Keryx Biopharmaceuticals' Common Stock Offering

Filed in archive Corporate and Industrial News on July 18, 2005

Keryx Biopharmaceuticals, Inc. announced yesterday the pricing of its public offering of 5,030,000 shares of its common stock at an offering price of $14.05 per share. J.P. Morgan Securities Inc. is acting as the sole book-running manager in this offering with Bear, Stearns & Co. Inc. acting as co-lead manager, and Jefferies & Company, Inc., Oppenheimer & Co. Inc., Brean Murray & Co., Inc. and Punk, Ziegel & Company, L.P. are acting as co-managers. The offering is expected to close on July 20, 2005.

About Keryx:Headquarters: New York City

Lead compounds under Development:KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening disease caused by diabetes. KRX-101 is in Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. A

KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase II clinical development for multiple tumor types.

More investor information here.